IP Library › Granted Patent US 11,478,555
Granted Patent B2
US 11,478,555 · App. 15/753,212 · Granted Oct 25, 2022

Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof

Inventors: Kyungho Choi (Goyang-si, KR); Hyung-Bae Park (Seoul, KR); Ji Eun Lee (Goyang-si, KR); Yumi Oh (Goyang-si, KR); Ki-Hyun Kim (Seoul, KR); Soohyun Kim (Seoul, KR); Hyori Kim (Seoul, KR); Junho Chung (Seongnam-si, KR)
Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
A61K47/6819A61K35/17A61K38/17A61K39/395A61K39/39558C07K16/16C07K16/2809C07K16/2818C12N15/85A61P35/00C07K2317/53C07K2317/622C07K2317/73C07K2319/02C07K2319/03C07K2319/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,478,555
App. No.
15/753,212
Granted
Oct 25, 2022
Kind
B2
Abstract

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Claims (17)

1. An isolated chimeric antigen receptor comprising, in the order from the N-terminus to the C-terminus of the chimeric antigen receptor, the following (a)-(d):

(a) an anti-cotinine single chain Fv (scFv) antibody, wherein the anti-cotinine scFv antibody comprises the amino acid sequence of SEQ ID NO: 1;

(b) a CD8 (cluster of differentiation 8) hinge domain comprising the sequence of SEQ ID NO: 3;

(c) a transmembrane domain of CD28 comprising the sequence of SEQ ID NO: 5 or 7; and

(d) a signal transduction domain selected from the group consisting of the following (i)-(iii):

(i) a CD28 cytoplasmic region comprising the sequence of SEQ ID NO: 9 or 11,

(ii) a CD3 zeta cytoplasmic region comprising the sequence of SEQ ID NO: 13, and

(iii) a CD28 cytoplasmic region comprising the sequence of SEQ ID NO: 9 or 11 and a CD3 zeta cytoplasmic region comprising the sequence of SEQ ID NO: 13.

2. The isolated chimeric antigen receptor of claim 1 , wherein the signal transduction domain is the (iii) CD28 cytoplasmic region comprising the sequence of SEQ ID NO: 9 or 11 and CD3 zeta cytoplasmic region comprising the sequence of SEQ ID NO: 13.

3. The isolated chimeric antigen receptor of claim 1 , wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 17.

4. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1 .

5. An isolated expression vector comprising the nucleic acid molecule of claim 4 .

6. The isolated expression vector of claim 5 , wherein the expression vector is a virus vector.

7. The isolated expression vector of claim 6 , wherein the virus vector is an adenovirus vector, a retrovirus vector, a lentivirus vector, or an adeno-associated virus vector.

8. An isolated virus comprising the nucleic acid molecule of claim 4 .

9. An isolated cell transduced with the virus of claim 8 .

10. The isolated cell of claim 9 , wherein the cell is a T cell, a natural killer cell, or a macrophage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2018
From: CHOI, KYUNGHO; PARK, HYUNG-BAE; LEE, JI EUN; OH, YUMI; KIM, KI-HYUN; KIM, SOOHYUN; KIM, HYORI; CHUNG, JUNHO
To: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Reel/Frame 044954/0158 →
Continuity (2)
Provisional Application 62205844 · Aug 17, 2015
Related Publication 20180256744A1 · Sep 13, 2018